Factors influencing timely diagnosis in neurolymphomatosis.
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
08 Aug 2024
08 Aug 2024
Historique:
received:
31
05
2024
accepted:
01
08
2024
medline:
8
8
2024
pubmed:
8
8
2024
entrez:
8
8
2024
Statut:
aheadofprint
Résumé
Neurolymphomatosis refers to infiltration of the peripheral nervous system (PNS) by non-Hodgkin lymphoma (NHL). Diagnostic intervals in neurolymphomatosis and factors delaying diagnosis have not been evaluated. We therefore aimed to analyze diagnostic intervals in a large cohort. The quality control database at Yale Cancer Center, Section of Neuro-Oncology, was searched for neurolymphomatosis cases diagnosed between 2001 and 2021. Univariate analyses were performed to identify parameters influencing diagnostic intervals. We identified 22 neurolymphomatosis cases including 7 with primary and 15 with secondary disease, which occurred a median (range: 4-144) of 16 months after initial NHL diagnosis. Patients typically presented with painful polyneuropathy (73%), that was asymmetrical and rapidly progressive. Diagnosis was based on PNS biopsy (50%) or integration of neuroimaging findings (50%) with NHL history and diagnostic cerebrospinal fluid examinations. Median interval from symptom onset to diagnosis was 3 months (range: 1-12). Secondary neurolymphomatosis compared to primary disease (median 2 vs. 6 months, p = 0.02), and cases with rapidly-progressive asymmetrical neuropathy as opposed to other presentations (median 2 vs. 6 months; p < 0.001) were diagnosed earlier. Upfront conventional CT compared to other modalities (median 2 vs. 5 months p = 0.04) and nerve root localization as opposed to other disease sites (median 1.5 vs. 4 months; p = 0.04) delayed diagnosis. NL type and localization, neuropathy course and distribution, and imaging modality selected for initial evaluation influence diagnostic intervals in neurolymphomatosis. Knowledge of this rare entity is critical for early suspicion, and diagnosis.
Sections du résumé
BACKGROUND
BACKGROUND
Neurolymphomatosis refers to infiltration of the peripheral nervous system (PNS) by non-Hodgkin lymphoma (NHL). Diagnostic intervals in neurolymphomatosis and factors delaying diagnosis have not been evaluated. We therefore aimed to analyze diagnostic intervals in a large cohort.
METHODS
METHODS
The quality control database at Yale Cancer Center, Section of Neuro-Oncology, was searched for neurolymphomatosis cases diagnosed between 2001 and 2021. Univariate analyses were performed to identify parameters influencing diagnostic intervals.
RESULTS
RESULTS
We identified 22 neurolymphomatosis cases including 7 with primary and 15 with secondary disease, which occurred a median (range: 4-144) of 16 months after initial NHL diagnosis. Patients typically presented with painful polyneuropathy (73%), that was asymmetrical and rapidly progressive. Diagnosis was based on PNS biopsy (50%) or integration of neuroimaging findings (50%) with NHL history and diagnostic cerebrospinal fluid examinations. Median interval from symptom onset to diagnosis was 3 months (range: 1-12). Secondary neurolymphomatosis compared to primary disease (median 2 vs. 6 months, p = 0.02), and cases with rapidly-progressive asymmetrical neuropathy as opposed to other presentations (median 2 vs. 6 months; p < 0.001) were diagnosed earlier. Upfront conventional CT compared to other modalities (median 2 vs. 5 months p = 0.04) and nerve root localization as opposed to other disease sites (median 1.5 vs. 4 months; p = 0.04) delayed diagnosis.
CONCLUSIONS
CONCLUSIONS
NL type and localization, neuropathy course and distribution, and imaging modality selected for initial evaluation influence diagnostic intervals in neurolymphomatosis. Knowledge of this rare entity is critical for early suspicion, and diagnosis.
Identifiants
pubmed: 39115616
doi: 10.1007/s11060-024-04792-2
pii: 10.1007/s11060-024-04792-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH (2003) Neurolymphomatosis Neuro Oncol 5(2):104–115
doi: 10.1215/15228517-5-2-104
pubmed: 12672282
Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D et al (2010) Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood 115(24):5005–5011
doi: 10.1182/blood-2009-12-258210
pubmed: 20368468
pmcid: 3710441
Baehring JM, Batchelor TT (2012) Diagnosis and management of neurolymphomatosis. Cancer J 18(5):463–468
doi: 10.1097/PPO.0b013e31826c5ad5
pubmed: 23006953
Kaulen LD, Foss FM, Fulbright RK, Huttner A, Baehring JM (2017) Neurolymphomatosis of the thoracic sympathetic chain. Neurology 89(18):1926–1927
doi: 10.1212/WNL.0000000000004600
pubmed: 28939669
pmcid: 5664295
Kaulen LD, Hielscher T, Doubrovinskaia S et al (2024) Clinical Presentation, Management, and Outcome in Neurolymphomatosis: A Systematic Review. Neurology103(4):e209698 https://doi.org/10.1212/WNL.0000000000209698
doi: 10.1212/WNL.0000000000209698
pubmed: 39102613
Viala K, Béhin A, Maisonobe T, Léger JM, Stojkovic T, Davi F et al (2008) Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg Psychiatry 79(7):778–782
doi: 10.1136/jnnp.2007.125930
pubmed: 17971432
Callaghan BC, Price RS, Feldman EL (2015) Distal symmetric polyneuropathy: a review. JAMA 314(20):2172–2181
doi: 10.1001/jama.2015.13611
pubmed: 26599185
pmcid: 5125083
Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL et al (2020) Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in survivors of adult cancers: ASCO Guideline Update. J Clin Oncol 38(28):3325–3348
doi: 10.1200/JCO.20.01399
pubmed: 32663120
Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7(11):1630–1636
doi: 10.1200/JCO.1989.7.11.1630
pubmed: 2809679
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068
doi: 10.1200/JCO.2013.54.8800
pubmed: 25113753
pmcid: 4979083
Khurana A, Novo M, Nowakowski GS, Ristow KM, Spinner RJ, Hunt CH et al (2021) Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the Rituximab era. Blood Adv 5(5):1379–1387
doi: 10.1182/bloodadvances.2020003666
pubmed: 33661298
pmcid: 7948277
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol.;32(27):3048-58
Barrington SF, Trotman J (2021) The role of PET in the first-line treatment of the most common subtypes of non-hodgkin lymphoma. Lancet Haematol 8(1):e80–e93
doi: 10.1016/S2352-3026(20)30365-3
pubmed: 33357487
Gabriel CM, Howard R, Kinsella N, Lucas S, McColl I, Saldanha G et al (2000) Prospective study of the usefulness of sural nerve biopsy. J Neurol Neurosurg Psychiatry 69(4):442–446
doi: 10.1136/jnnp.69.4.442
pubmed: 10990501
pmcid: 1737127
Hilton DA, Jacob J, Househam L, Tengah C (2007) Complications following sural and peroneal nerve biopsies. J Neurol Neurosurg Psychiatry 78(11):1271–1272
doi: 10.1136/jnnp.2007.116368
pubmed: 17550992
pmcid: 2117606
Haldorsen IS, Espeland A, Larsen JL, Mella O (2005) Diagnostic delay in primary central nervous system lymphoma. Acta Oncol 44(7):728–734
doi: 10.1080/02841860500256272
pubmed: 16227164
Velasco R, Mercadal S, Vidal N, Alañá M, Barceló MI, Ibáñez-Juliá MJ et al (2020) Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. J Neurooncol 148(3):545–554
doi: 10.1007/s11060-020-03547-z
pubmed: 32524392
Allgar VL, Neal RD (2005) Delays in the diagnosis of six cancers: analysis of data from the National Survey of NHS patients: Cancer. Br J Cancer 92(11):1959–1970
doi: 10.1038/sj.bjc.6602587
pubmed: 15870714
pmcid: 2361797
Lehmann HC, Wunderlich G, Fink GR, Sommer C (2020) Diagnosis of peripheral neuropathy. Neurol Res Pract 2(1):20
doi: 10.1186/s42466-020-00064-2
pubmed: 33324924
pmcid: 7650053
Lyratzopoulos G, Wardle J, Rubin G (2014) Rethinking diagnostic delay in cancer: how difficult is the diagnosis? BMJ 349:g7400
doi: 10.1136/bmj.g7400
pubmed: 25491791
Selby P, Popescu R, Lawler M, Butcher H, Costa A (2019) The Value and Future developments of Multidisciplinary Team Cancer Care. Am Soc Clin Oncol Educ Book 39:332–340
doi: 10.1200/EDBK_236857
pubmed: 31099640
Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL et al (2019) Diabetic neuropathy. Nat Reviews Disease Primers 5(1):41
doi: 10.1038/s41572-019-0092-1
pubmed: 31197153
Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL (2012) Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 11(6):521–534
doi: 10.1016/S1474-4422(12)70065-0
pubmed: 22608666
Brinjikji W, Luetmer PH, Comstock B, Bresnahan BW, Chen LE, Deyo RA et al (2015) Systematic literature review of imaging features of spinal degeneration in asymptomatic populations. AJNR Am J Neuroradiol 36(4):811–816
doi: 10.3174/ajnr.A4173
pubmed: 25430861
Gupta M, Burns EJ, Georgantas NZ, Thierauf J, Nayyar N, Gordon A et al (2021) A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood 138(5):382–386
doi: 10.1182/blood.2020010137
pubmed: 33735913
Mutter JA, Alig SK, Esfahani MS, Lauer EM, Mitschke J, Kurtz DM et al (2023) Circulating tumor DNA profiling for detection, risk stratification, and classification of Brain Lymphomas. J Clin Oncol 41(9):1684–1694
doi: 10.1200/JCO.22.00826
pubmed: 36542815
Alix-Panabières C, Pantel K (2021) Liquid Biopsy: from Discovery to Clinical Application. Cancer Discov 11(4):858–873
doi: 10.1158/2159-8290.CD-20-1311
pubmed: 33811121
Ferreri AJM, Calimeri T, Lopedote P, Francaviglia I, Daverio R, Iacona C et al (2021) MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. Br J Haematol 193(3):497–505
doi: 10.1111/bjh.17357
pubmed: 33620087
Kaulen LD, Erson-Omay EZ, Henegariu O, Karschnia P, Huttner A, Günel M et al (2021) Exome sequencing identifies SLIT2 variants in primary CNS lymphoma. Br J Haematol 193(2):375–379
doi: 10.1111/bjh.17319
pubmed: 33481259
Kaulen LD, Denisova E, Hinz F, Hai L, Friedel D, Henegariu O et al (2023) Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas. Acta Neuropathol 146(3):499–514
doi: 10.1007/s00401-023-02613-w
pubmed: 37495858
pmcid: 10412493
Kaulen LD, Baehring JM (2022) Treatment Options for Recurrent Primary CNS Lymphoma. Curr Treat Options Oncol 23(11):1548–1565
doi: 10.1007/s11864-022-01016-5
pubmed: 36205806
Grommes C, Nayak L, Tun HW, Batchelor TT (2019) Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro Oncol 21(3):306–313
doi: 10.1093/neuonc/noy193
pubmed: 30423172
Kaulen LD, Gumbinger C, Hinz F, Kessler T, Winkler F, Bendszus M et al (2022) Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma. Neurooncol Adv 4(1):vdac051
pubmed: 35571985
pmcid: 9092640